← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Dipeptidyl peptidase 4 (DPP-4) inhibitors
gemigliptin and rosuvastatin
A10BH52
Forms & Strengths
- Gemigliptin 50mg and Rosuvastatin 5mg
- Gemigliptin 50mg and Rosuvastatin 10mg
- Gemigliptin 50mg and Rosuvastatin 20mg
- Tablet form
Adult Dosing
- One tablet orally once daily
- Dose adjustment may be needed based on renal function
- Maximum dose: Gemigliptin 50mg and Rosuvastatin 20mg
Pediatric Dosing
- Safety and efficacy not established in patients under 18 years old
Indications
- Treatment of type 2 diabetes mellitus
- Primary hyperlipidemia
- Mixed dyslipidemia
Mechanism of Action
- Gemigliptin: Inhibits dipeptidyl peptidase-4 (DPP-4), increasing glucose-dependent insulin secretion
- Rosuvastatin: Selectively and competitively inhibits HMG-CoA reductase, reducing cholesterol synthesis
Contraindications
- Hypersensitivity to gemigliptin, rosuvastatin, or any excipients
- Active liver disease
- Pregnancy and breastfeeding
- Concomitant use of cyclosporine
Adverse Reactions
- Hypoglycemia
- Headache
- Nasopharyngitis
- Myalgia
- Increased liver enzymes
- Rhabdomyolysis (rare)
Drug Interactions
- Gemfibrozil: Increased risk of myopathy
- Cyclosporine: Increased risk of rhabdomyolysis
- Warfarin: Increased INR, monitor carefully
- Lopinavir/ritonavir or atazanavir: Increased rosuvastatin exposure
Curated Content: Needs Vetting Before Put to Clinical Use